ArriVent BioPharma, Inc. reports news as a clinical-stage biopharmaceutical company developing oncology therapeutics. Company updates center on firmonertinib, an EGFR inhibitor for EGFR mutant non-small cell lung cancer, including exon 20 insertion and PACC mutation settings, as well as regulatory designations, clinical data presentations, and global study activity.
Recurring developments also cover ArriVent's antibody-drug conjugate portfolio, including ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies, and ARR-002, a MUC16/NaPi2b targeting tetravalent ADC with an initial focus in ovarian and endometrial cancers. News releases also include IND clearances, oncology conference presentations, financial results, collaborations, and executive or commercial organization updates.
ArriVent BioPharma reported strong financial results for the first quarter of 2024, with a cash position of $317.4 million, showcasing positive progress in advancing their clinical programs. The company presented preclinical data on firmonertinib at the AACR Annual Meeting, demonstrating its effectiveness across a wide range of mutations in NSCLC. They also dosed the first patient in a Phase 1b combination study with ICP-189 for NSCLC patients with EGFR classical mutations. The company is on track to deliver proof-of-concept data in 2024 and is making strides in selecting a next-generation ADC development candidate.
Summary not available.
Summary not available.
Summary not available.